Novel Liposomal Amphotericin B (Cat-LAmB) for Treatment of Visceral Leishmaniasis and Fungal Infections.

Our studies with this formulation demonstrated very potent antifungal efficacy both in invitro and invivo in comparison with Ambisome. Thus, this formulation has prospects for the treatment of severe and complicated invasive fungal infections making it a lucrative commercial product. Moreover, for better stability lyophlisation was necessary for which we standardised the lyophilisation conditions and were able to successfully lyophilise the liposomal AmB formulation.

The combination of PC-SA with AmB provides the immunomodulatory effect comparable with that of the AmB deoxycholate with least toxicity. Although Ambisomereduces the toxicity, the immunomodulatory effects of AmB is masked. The single shot treatment with Cat-LAmB offers enhanced efficacy, reduced toxicity, and improved pharmacokinetics compared to conventional anti-leishmanial and antifungal therapies such as amphotericin B deoxycholate, AmBisome and Fungisome. 

Complete cure of visceral leishmaniasis and resistance to relapse and reinfection.